_WHAT’S HAPPENING_
President Trump recently instituted a number of health policy changes amid ongoing shakeups centered on fertility and pregnancy, abortion policy, and the direction of federal health agencies.
Over the weekend, the administration proposed a new rule allowing employers to voluntarily offer fertility treatment coverage as an excepted benefit. On Mother’s Day, the White House launched a new website to provide pregnancy and parenting resources. And yesterday, Food and Drug Administration (FDA) Commissioner Dr. Marty Makary resigned following mounting pressure from pro-life advocates and internal friction with Health and Human Services Secretary (HHS) Robert F. Kennedy Jr.
Follow the full story: MAHA and RFK Jr.'s health agenda
_THE FACTS_
The Trump administration proposed a new rule that would create an exemption for insurance benefits covering fertility treatments, similar to dental and vision coverage.
The administration also launched Moms.gov on Mother's Day, providing resources on breastfeeding, mental health, nutrition, and adoption for expecting families.
During an Oval Office press conference with the president, HHS Secretary RFK Jr. called the declining birth rate an "existential crisis,” claiming men in 1970 had twice the sperm count of teenagers today.
Kennedy stated the department is studying how obesity, chemicals, and pesticides may affect fertility, warning of a “toxic soup that our young women are walking around in.”
FDA Commissioner Marty Makary resigned Tuesday following pressure from pro-life groups who were frustrated with his handling of abortion drug mifepristone.
Under Makary's leadership, the FDA left Biden-era rules intact that allowed mifepristone to be prescribed online and mailed, and approved a new generic version of the pill.
Republican Sen. Josh Hawley (MO) called Makary's resignation "welcome news," saying he "attempted to place pro-abortion lawyers in key positions" and "slow walked a vitally necessary review of the abortion drug mifepristone."
Kyle Diamantas, formerly the agency’s top food official, will serve as acting FDA chief.
_OUR TAKE_
The change in leadership at the FDA reveals a tension inside the White House. Kennedy was reportedly pushing for Makary to leave, and in the aftermath of the announcement, many Republican lawmakers voiced their support for the move.
Pro-lifers in Trump’s coalition expected a more forceful rollback of Biden-era abortion pill policies, suggesting that abortion policy remains a live fault line in the current White House. It’s also not a coincidence that, simultaneous to Makary’s ousting for being insufficiently pro-life, Kennedy is focusing on declining fertility — a life issue — even tying it to environmental factors in a way that echoes MAHA’s priorities.
These changes offer to reinvigorate the Department of Health and Human Services, giving the Trump administration another avenue to argue it is delivering tangible results for Americans.













